Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort
暂无分享,去创建一个
M. Kuo | Ming‐Lung Yu | Kun-Der Lin | H. Hsiao | M. Yeh | Chung‐Feng Huang | C. Dai | Po-Cheng Liang | W. Chuang | Chun-Yuan Lee | M. Hsieh | Tun-Chieh Chen | Sheng-Fan Wang | Chih-Wen Wang | Tyng-Yuan Jang | Po-Yao Hsu | Yen-Hsu Chen | Yu-Ju Wei | Shuo-Hung Wang | C. Hsu | P. Wu | Chien-Tzu Huang | M. Yu | Yi‐Hung Lin | Ching-I Huang | Jee‐Fu Huang | Chung-Feng Huang | Ming‐Yen Hsieh | Ming‐Lung Yu
[1] C. Agrati,et al. Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV , 2022, Nature Communications.
[2] Chris Nakas,et al. Antibody titers after a third dose of the SARS‐CoV‐2 BNT162b2 vaccine in immunocompromised adults in Greece: Is a fourth dose necessary? , 2022, Journal of medical virology.
[3] Philip R. O. Payne,et al. Estrogen hormone is an essential sex factor inhibiting inflammation and immune response in COVID-19 , 2022, Scientific Reports.
[4] G. Antonelli,et al. Serological Response and Relationship with Gender-Sensitive Variables among Healthcare Workers after SARS-CoV-2 Vaccination , 2022, Journal of personalized medicine.
[5] Tyng-Yuan Jang. Liver injury caused by SARS-CoV-2 Delta and Omicron-variant in Taiwan , 2022, Journal of the Formosan Medical Association.
[6] Tyng-Yuan Jang. Why cannot Taiwan be COVID-19 free? , 2022, Journal of the Formosan Medical Association.
[7] R. Halperin,et al. A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients , 2022, Journal of Hepatology.
[8] Henrik Nielsen,et al. Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study , 2022, Clinical Microbiology and Infection.
[9] Ming‐Lung Yu,et al. Clinical characteristics and treatment outcomes of SARS-CoV-2 delta variant outbreak, Pingtung, Taiwan, June 2021 , 2022, Journal of the Formosan Medical Association.
[10] A. Hoerauf,et al. Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 Vaccines , 2021, Frontiers in Immunology.
[11] Anthony Z. Matolek,et al. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans — Five Veterans Affairs Medical Centers, United States, February 1–September 30, 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[12] E. Callaway. Mix-and-match COVID vaccines ace the effectiveness test. , 2021, Nature.
[13] Michael I. Mandel,et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel , 2021, The New England journal of medicine.
[14] V. Caudwell,et al. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis , 2021, American Journal of Kidney Diseases.
[15] Jinseog Kim,et al. Age-adjusted Charlson comorbidity index score is the best predictor for severe clinical outcome in the hospitalized patients with COVID-19 infection , 2021, Medicine.
[16] J. V. Van Eyk,et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 , 2021, Nature Medicine.
[17] Kang Zhang,et al. COVID-19 in early 2021: current status and looking forward , 2021, Signal Transduction and Targeted Therapy.
[18] Chris Nakas,et al. Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers , 2021, Journal of medical microbiology.
[19] Chi-kung Ho,et al. 222 days without COVID in Taiwan: what are the reasons for this success? , 2021, Journal of Travel Medicine.
[20] R. Olsthoorn,et al. Structural phylogenetic analysis reveals lineage-specific RNA repetitive structural motifs in all coronaviruses and associated variations in SARS-CoV-2 , 2021, Virus evolution.
[21] A. Pollard,et al. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2 , 2020, The Lancet Infectious Diseases.
[22] N. Wilson,et al. Potential lessons from the Taiwan and New Zealand health responses to the COVID-19 pandemic , 2020, The Lancet Regional Health - Western Pacific.
[23] J. A. Cook,et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study , 2020, Journal of Hepatology.
[24] K. Bhaskaran,et al. Factors associated with COVID-19-related death using OpenSAFELY , 2020, Nature.
[25] K. Bhaskaran,et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.
[26] R. Brook,et al. Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing. , 2020, JAMA.
[27] Yi-Chi Wu,et al. The outbreak of COVID-19: An overview , 2020, Journal of the Chinese Medical Association : JCMA.
[28] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[29] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.